This melanoma antigen gp100-targeted vaccine was recently evaluated in patients with pretreated, unresectable stage IIIB/C/IV melanoma and displayed encouraging clinical tumor response, activation of gp100-specific CD8+ T cells as well as an excellent safety profile (11). This evidence concerns the gene PMEL and melanoma.